サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1584097

タミフル市場：剤形別、薬剤タイプ別、適応症別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、2024-2032年予測

Tamiflu Market, By Dosage Form, By Drug Type, By Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 322 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
タミフル市場：剤形別、薬剤タイプ別、適応症別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、2024-2032年予測
出版日: 2024年10月26日
発行: AnalystView Market Insights
ページ情報: 英文 322 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

タミフル市場規模は2023年に19億2,032万米ドルとなり、2024年から2032年にかけてCAGR 3.40%で拡大

タミフル市場-市場力学

世界の季節性インフルエンザの流行とCOVID-19パンデミック時の需要増加が市場需要を促進

タミフル（リン酸オセルタミビル）は抗ウイルス薬で、2日以内にインフルエンザの症状が現れた生後2週間以上の患者を対象に、急性で合併症のないインフルエンザA型およびB型、豚インフルエンザ（H1N1）の治療に適応があります。カプセルと経口懸濁液の2種類があります。タミフル（リン酸オセルタミビル）市場は、比較的副作用が軽いことから、世界の季節性インフルエンザの流行増加やCOVID-19パンデミック時の需要増に牽引され、予測期間中に成長すると予想されています。さらに、多くの製薬会社がリン酸オセルタミビルのジェネリック医薬品を発売していることも、市場拡大に拍車をかけると予想されます。タミフルはA型、B型、豚インフルエンザの治療に適応があるため、世界のインフルエンザ患者の増加が市場を押し上げると予想されます。例えば、世界保健機関（WHO）の2021年11月の報告書によると、2020年には世界で300万～500万件の重症インフルエンザ患者が発生しています。

タミフル市場-主要洞察

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2024-2032年）に約3.40%のCAGRで毎年成長すると推定されます。

薬剤タイプ別では、ジェネリック医薬品が2023年に最大の市場シェアを示すと予測されています。

剤形別では、2023年にはカプセルが主要タイプに

地域別では、北米が2023年の売上高でトップ

タミフル市場-セグメンテーション分析：

タミフルの世界市場は、剤形、薬剤タイプ、適応症、流通チャネル、地域によって区分されます。

薬剤の種類により、市場は先発品とジェネリックの2つに分類されます。ジェネリック医薬品は、季節性インフルエンザの治療におけるリン酸オセルタミビルの高い需要に牽引され、予測期間中、市場を独占すると予想されます。タミフルのジェネリック医薬品は、より費用対効果の高いソリューションであるため、幅広い患者やヘルスケア・システムにとって利用しやすくなっています。この手頃な価格は、先発医薬品と同等の有効性と相まって、特にコストに敏感なヘルスケアモデルを持つ地域において、ジェネリック医薬品が強く好まれる要因となっています。さらに、タミフルの特許切れ後、多くの製薬会社がジェネリック医薬品を発売したため、市場競争は激化し、価格はさらに低下し、入手しやすくなっています。

市場は剤形によってカプセルと懸濁液の2つに分類されます。カプセルはインフルエンザ治療に広く使用されているため、予測期間を通じて市場をリードすると予想されます。カプセルは利便性が高く、投与が容易で、合併症のないインフルエンザの治療において患者やヘルスケアプロバイダーに好まれています。さらに、カプセルは懸濁製剤に比べて安定性が高く、保存期間が長いため、備蓄や流通に適しています。一方、経口懸濁液は一般的に、幼児や特定の病状を持つ人など、カプセルを飲み込むことができない患者にのみ使用されます。タミフルは、このような人々にとって利用しやすさを確保する上で重要な役割を果たすが、経口懸濁液の需要はカプセル剤に比べて依然として低く、後者の市場優位性が強まっています。

タミフル市場-地理的洞察

予測期間中、北米地域がタミフル市場を独占すると予想されるが、その主な理由は、市場シェアが大きいことと、今後のインフルエンザシーズンに備えてタミフルの備蓄が増加していることです。例えば、米国政府は2022年12月21日、米国保健福祉省（HHS）が戦略的準備・対応局（ASPR）と共同で、2022年のインフルエンザシーズン中の需要増に対応するため、タミフルの追加備蓄を行うと発表しました。これは戦略的国家備蓄（SNS）を通じて実現しました。政府はASPR地域チームと協力して、SNSからのタミフル配布要請を評価し、州、準州、部族が必要な支援を受けられるようにするとともに、将来の新型インフルエンザ発生への備えを維持します。

タミフル市場-競合情勢：

タミフル市場の各社は、競争力を高め市場シェアを拡大するため、さまざまな戦略を実施しています。これには、インフルエンザの予防と治療についてヘルスケアプロバイダーや一般市民を啓蒙することを目的とした強力なマーケティングキャンペーンが含まれます。企業はまた、政府や保健機関との提携を優先し、インフルエンザの流行期やパンデミック時に抗ウイルス薬を備蓄する契約を確保しています。研究開発努力も重要で、新型インフルエンザに対抗する次世代の抗ウイルス療法を開発することに重点を置いた投資を行っています。さらに、価格戦略は、必要とする患者への幅広いアクセスを確保しながら、ヘルスケアシステムの予算に合わせるように設計されています。

目次

第1章 タミフル市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 タミフルの主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 タミフル業界の研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 タミフル市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 タミフル市場情勢

  • タミフル市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 タミフル市場- 剤形別

  • 概要
    • 剤形別セグメントシェア分析
    • カプセル
    • 懸濁剤

第8章 タミフル市場- 薬剤タイプ別

  • 概要
    • 薬剤タイプ別セグメントシェア分析
    • ブランド
    • ジェネリック

第9章 タミフル市場- 適応症別

  • 概要
    • 適応症別セグメントシェア分析
    • インフルエンザA
    • インフルエンザB
    • 豚インフルエンザ（H1N1インフルエンザA）

第10章 タミフル市場- 流通チャネル別

  • 概要
    • 流通チャネル別セグメントシェア分析
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第11章 タミフル市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析- タミフル業界

  • 競争ダッシュボード
  • 企業プロファイル
    • F. Hoffmann-La Roche Ltd.
    • NATCO Pharma Limited
    • Teva Pharmaceutical Industries Ltd
    • LUPIN Limited
    • Amneal pharmaceuticals LLC
    • Zydus Cadila
    • Sun Pharmaceutical Industries Ltd.
    • Alembic Pharmaceuticals Limited
    • Mylan NV
    • Hetero Group
    • Others

第13章 アナリストの全方位展望

目次
Product Code: ANV4087

REPORT HIGHLIGHT

Tamiflu Market size was valued at USD 1,920.32 Million in 2023, expanding at a CAGR of 3.40% from 2024 to 2032.

Tamiflu, also known as oseltamivir, is an antiviral medication commonly used to treat and prevent influenza infections. It works by inhibiting neuraminidase enzyme, which the virus needs to spread within the respiratory system. Tamiflu is most effective in reducing flu symptoms' duration and severity when taken within the first 48 hours of symptom onset. It can also be prescribed as a preventive measure for individuals at high risk of complications from the flu. Due to its effectiveness, Tamiflu is critical in public health efforts during flu outbreaks and pandemics.

Tamiflu Market- Market Dynamics

Increasing prevalence of seasonal influenza worldwide and increased demand during the COVID-19 pandemic to propel market demand

Tamiflu (oseltamivir phosphate) is an antiviral medication indicated for the treatment of acute, uncomplicated influenza A and B, as well as swine flu (H1N1), in patients aged two weeks and older who have had flu symptoms for less than two days. It is available in both capsule and oral suspension forms. The market for Tamiflu (oseltamivir phosphate) is expected to grow over the forecast period, driven by the rising prevalence of seasonal influenza worldwide and increased demand during the COVID-19 pandemic, due to its relatively mild side effects. Additionally, the launch of generic versions of oseltamivir phosphate by many pharmaceutical companies is anticipated to further fuel market expansion. As Tamiflu is indicated for treating influenza A, B, and swine flu, the global rise in influenza cases is expected to boost the market. For instance, according to a November 2021 report by the World Health Organization, in 2020, there were 3 to 5 million cases of severe influenza illness globally.

Tamiflu Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.40% over the forecast period (2024-2032)

Based on Drug Type segmentation, generic was predicted to show maximum market share in the year 2023

Based on Dosage Form segmentation, capsules was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Tamiflu Market- Segmentation Analysis:

The Global Tamiflu Market is segmented on the basis of Dosage Form, Drug Type, Indication, Distribution Channel, and Region.

The market is divided into two categories based on Drug Type: branded and generic options. The generic segment is anticipated to dominate the market during the forecast period, largely driven by the high demand for oseltamivir phosphate in treating seasonal influenza. Generic versions of Tamiflu offer a more cost-effective solution, making them more accessible to a broader range of patients and healthcare systems. This affordability, coupled with comparable efficacy to branded drugs, contributes to the strong preference for generics, especially in regions with cost-sensitive healthcare models. Additionally, as many pharmaceutical companies have launched generic alternatives following the expiration of Tamiflu's patent, the market has seen increased competition, further driving down prices and boosting the availability of the drug.

The market is divided into two categories based on Dosage Form: capsules and suspension. The capsule segment is expected to lead the market throughout the forecast period due to its widespread preference for treating influenza. Capsules are convenient, easy to administer, and typically preferred by patients and healthcare providers alike for treating uncomplicated influenza cases. Furthermore, capsules offer more stability and have a longer shelf life compared to suspensions, making them more practical for stockpiling and distribution. Oral suspension, on the other hand, is generally reserved for patients who are unable to swallow capsules, such as young children or individuals with specific medical conditions. While it serves an important role in ensuring accessibility for these populations, the demand for oral suspension remains lower compared to capsules, reinforcing the latter's market dominance.

Tamiflu Market- Geographical Insights

The North America region is expected to dominate the Tamiflu market during the forecast period, primarily due to its significant market share and the increased stockpiling of Tamiflu in preparation for upcoming influenza seasons. For example, on December 21, 2022, the U.S. government announced that the U.S. Department of Health and Human Services (HHS), in collaboration with the Administration for Strategic Preparedness and Response (ASPR), is storing additional supplies of Tamiflu to meet rising demand during the 2022 flu season. This was achieved through the Strategic National Stockpile (SNS). The government, working with ASPR Regional Teams, will assess requests for Tamiflu distribution from the SNS, ensuring that states, territories, and tribes receive necessary support while maintaining preparedness for future pandemic influenza outbreaks.

Tamiflu Market- Competitive Landscape:

Companies in the Tamiflu market implement a range of strategies to improve their competitive position and increase market share. These include robust marketing campaigns aimed at educating healthcare providers and the public about flu prevention and treatment. Firms also prioritize partnerships with governments and health organizations to secure contracts for stockpiling antiviral medications during flu seasons or pandemics. Research and development efforts are important as well, with investments focused on creating next-generation antiviral therapies to combat emerging influenza strains. Further, pricing strategies are designed to align with healthcare system budgets while ensuring broad access for patients in need.

Recent Developments:

In December 2022, Genentech, Inc., U.S. biotechnology corporation, announced that Tamiflu (oseltamivir phosphate) was available for distribution across the U.S., enabling drug shipments to pharmacies nationwide.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL TAMIFLU MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • F. Hoffmann-La Roche Ltd.
  • NATCO Pharma Limited
  • Teva Pharmaceutical Industries Ltd
  • LUPIN Limited
  • Amneal pharmaceuticals LLC
  • Zydus Cadila
  • Sun Pharmaceutical Industries Ltd.
  • Alembic Pharmaceuticals Limited
  • Mylan N.V.
  • Hetero Group
  • Others

GLOBAL TAMIFLU MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032

  • Capsules
  • Suspension

GLOBAL TAMIFLU MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Branded
  • Generic options

GLOBAL TAMIFLU MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Influenza A
  • Influenza B
  • Swine Flu (H1N1 Influenza A)

GLOBAL TAMIFLU MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

GLOBAL TAMIFLU MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Tamiflu Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Tamiflu Market Snippet by Dosage Form
    • 2.1.2. Tamiflu Market Snippet by Drug Type
    • 2.1.3. Tamiflu Market Snippet by Indication
    • 2.1.4. Tamiflu Market Snippet by Distribution Channel
    • 2.1.5. Tamiflu Market Snippet by Country
    • 2.1.6. Tamiflu Market Snippet by Region
  • 2.2. Competitive Insights

3. Tamiflu Key Market Trends

  • 3.1. Tamiflu Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Tamiflu Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Tamiflu Market Opportunities
  • 3.4. Tamiflu Market Future Trends

4. Tamiflu Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Tamiflu Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Tamiflu Market Landscape

  • 6.1. Tamiflu Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Tamiflu Market - By Dosage Form

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Dosage Form, 2023 & 2032 (%)
    • 7.1.2. Capsules
    • 7.1.3. Suspension

8. Tamiflu Market - By Drug Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 8.1.2. Branded
    • 8.1.3. Generic options

9. Tamiflu Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 9.1.2. Influenza A
    • 9.1.3. Influenza B
    • 9.1.4. Swine Flu (H1N1 Influenza A)

10. Tamiflu Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 10.1.2. Hospital pharmacies
    • 10.1.3. Retail pharmacies
    • 10.1.4. Online pharmacies

11. Tamiflu Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Tamiflu Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Tamiflu Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Tamiflu Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Tamiflu Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Tamiflu Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Tamiflu Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. F. Hoffmann-La Roche Ltd.
    • 12.2.2. NATCO Pharma Limited
    • 12.2.3. Teva Pharmaceutical Industries Ltd
    • 12.2.4. LUPIN Limited
    • 12.2.5. Amneal pharmaceuticals LLC
    • 12.2.6. Zydus Cadila
    • 12.2.7. Sun Pharmaceutical Industries Ltd.
    • 12.2.8. Alembic Pharmaceuticals Limited
    • 12.2.9. Mylan N.V.
    • 12.2.10. Hetero Group
    • 12.2.11. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us